The withdrawal is a procedural change with no immediate financial impact. Monitor for any future proxy filing regarding a revised equity plan proposal. The annual meeting proceeds as scheduled with the remaining proposals.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $3.67entry
- T+1 · 6mo ago +0.27%α +0.13% · $3.68
- T+5 · 5mo ago −11.44%α −8.69% · $3.25
- T+20 · 5mo ago −15.26%α −13.96% · $3.11
- T+60 · 3mo ago −12.26%α −13.49% · $3.22
Price Chart
How similar events traded
Executive Summary
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026 annual meeting agenda, citing further review. The remaining five proposals (director elections, ratification of auditor, say-on-pay, etc.) will proceed as scheduled. Existing proxy cards remain valid; no new voting instructions are needed.
Key Financial Metrics
Key Facts
- Proposal 3 (amendment to 2019 Stock Option and Incentive Plan) withdrawn from the 2026 annual meeting agenda.
- Board determined on May 31, 2026, not to seek stockholder approval of Proposal 3.
- All other proposals (1, 2, 4, 5, 6) remain on the agenda for the June 9, 2026 meeting.
- Record date remains April 20, 2026; existing proxy cards remain valid without resubmission.
- Company reserves right to propose future amendments to the equity compensation plan.
Financial Impact
No direct financial impact; removal of equity plan vote removes potential dilution from future option grants, but no dollar amounts disclosed.
Risk Factors
- Potential future dilution if a revised equity plan is proposed later.
- No material risk from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-249726 |
| Document: 0001193125-26-249726-index-headers.html | 0001193125-26-249726 |
| Document: 0001193125-26-249726-index.html | 0001193125-26-249726 |
| Document: 0001193125-26-249726.txt | 0001193125-26-249726 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers